August 30, 2016 1:30 AM ET

Life Sciences Tools and Services

Company Overview of NeuroGenetic Pharmaceuticals, Inc.

Company Overview

NeuroGenetic Pharmaceuticals, Inc., a biotech company, offers gamma-secretase modulators for the prevention of Alzheimer’s disease. It provides NGP 555, a small molecule modulator of the gamma-secretase complex, which crosses the blood-brain barrier and is used in lowering the brain biomarkers Aß42 and Aß40 while showing an increase in the Aß38 peptide with no effect on Notch processing. NeuroGenetic Pharmaceuticals, Inc. was founded in 2009 and is based in Del Mar, California.

445 Marine View Avenue

Suite 101

Del Mar, CA 92014

United States

Founded in 2009

Phone:

858-461-4480

Fax:

858-461-4485

Key Executives for NeuroGenetic Pharmaceuticals, Inc.

Co-Founder, Chairman, Chief Executive Officer and President
Age: 80
Co-Founder
Age: 58
Toxicology Consultant
Clinical Consultant
Compensation as of Fiscal Year 2016.

NeuroGenetic Pharmaceuticals, Inc. Key Developments

NeuroGenetic Pharmaceuticals, Inc. Presents at 14th Annual BIO Investor Forum, Oct-20-2015 02:45 PM

NeuroGenetic Pharmaceuticals, Inc. Presents at 14th Annual BIO Investor Forum, Oct-20-2015 02:45 PM. Venue: Parc 55 Hotel, San Francisco, California, United States.

NeuroGenetic Pharmaceuticals, Inc. Presents at Biocom's Global Life Science Partnering Conference, Feb-25-2015 11:00 AM

NeuroGenetic Pharmaceuticals, Inc. Presents at Biocom's Global Life Science Partnering Conference, Feb-25-2015 11:00 AM. Venue: The Lodge at Torrey Pines, 11480 North Torrey Pines Road, La Jolla, CA 92037, United States.

The U.S. Food and Drug Administration Approves NeuroGenetic Pharmaceuticals, Inc. Application to Begin Clinical Trials for its NGP 555

The U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application from NeuroGenetic Pharmaceuticals, Inc. (NGP) to begin clinical trials on its NGP 555 compound to treat and prevent Alzheimer's disease (AD). The approval follows successful completion of all preclinical phases under a fast-track grant from the National Institute of Neurologic Disease and Stroke (NINDS). NGP 555, a proprietary "first in class" molecule for the treatment/prevention of Alzheimer's disease, is a gamma-secretase modulator (GSM) demonstrating good brain penetration and targeting the gamma-secretase complex, a key enzyme in the amyloid pathway.

Similar Private Companies By Industry

Company Name Region
10X Genomics, Inc. United States
4G Clinical, Inc. United States
AAPharmaSyn LLC United States
Abiant, Inc. United States
aBioBot, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact NeuroGenetic Pharmaceuticals, Inc., please visit www.neurogeneticpharmaceuticals.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.